"Neoplasm Staging" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Descriptor ID |
D009367
|
MeSH Number(s) |
E01.789.625
|
Concept/Terms |
Neoplasm Staging- Neoplasm Staging
- Staging, Neoplasm
- Tumor Staging
- Staging, Tumor
- Cancer Staging
- Staging, Cancer
TNM Staging- TNM Staging
- Staging, TNM
- TNM Staging System
- Staging System, TNM
- Staging Systems, TNM
- System, TNM Staging
- Systems, TNM Staging
- TNM Staging Systems
- TNM Classification
- Classification, TNM
- Classifications, TNM
- TNM Classifications
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Staging".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Staging".
This graph shows the total number of publications written about "Neoplasm Staging" by people in this website by year, and whether "Neoplasm Staging" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1996 | 0 | 1 | 1 |
1997 | 0 | 6 | 6 |
1998 | 0 | 3 | 3 |
1999 | 0 | 2 | 2 |
2000 | 1 | 4 | 5 |
2001 | 2 | 7 | 9 |
2002 | 0 | 7 | 7 |
2003 | 0 | 7 | 7 |
2004 | 0 | 10 | 10 |
2005 | 2 | 11 | 13 |
2006 | 0 | 13 | 13 |
2007 | 0 | 17 | 17 |
2008 | 1 | 18 | 19 |
2009 | 4 | 16 | 20 |
2010 | 0 | 18 | 18 |
2011 | 0 | 23 | 23 |
2012 | 0 | 12 | 12 |
2013 | 1 | 21 | 22 |
2014 | 0 | 24 | 24 |
2015 | 0 | 16 | 16 |
2016 | 2 | 21 | 23 |
2017 | 0 | 23 | 23 |
2018 | 0 | 15 | 15 |
2019 | 2 | 9 | 11 |
2020 | 1 | 14 | 15 |
2021 | 0 | 16 | 16 |
2022 | 0 | 7 | 7 |
2023 | 0 | 2 | 2 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Staging" by people in Profiles.
-
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
-
Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO Precis Oncol. 2024 Jun; 8:e2300362.
-
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70?years and over. Gynecol Oncol. 2024 08; 187:221-226.
-
Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer. JAMA Netw Open. 2023 04 03; 6(4):e238437.
-
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
-
Innovative Imaging Techniques Used to Evaluate Borderline-Resectable Pancreatic Adenocarcinoma. J Surg Res. 2023 04; 284:42-53.
-
Association of Age and Overall Survival in Surgically Resected Colorectal Cancer Patients. J Surg Res. 2023 Jan; 281:321-327.
-
Neoadjuvant QUAD shot for downstaging or temporizing locally advanced oral cavity cancer prior to definitive surgery. Oral Oncol. 2022 10; 133:106029.
-
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (=10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecol Oncol. 2022 09; 166(3):410-416.
-
Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. Gynecol Oncol. 2022 07; 166(1):90-99.